Three Novel Myeloma Therapies April 24, 2021 Myeloma Round Table

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Peter Voorhees, MD, is Director of Outreach and Clinical Operations for Hematologic Malignancies and a Member of the Plasma Cells Disorder Program at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees is an internationally recognized thought leader in multiple myeloma whose research focuses on the clinical development of novel therapeutic strategies for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. He is board certified in Hematology and a member of the American Society of Hematology, American Society of Clinical Oncology and International Myeloma Working Group. He is also a member of the Multiple Myeloma Committee of the Alliance Cooperative Group. He has published numerous original articles, reviews and book chapters in multiple myeloma. He received his medical degree from the University of Michigan, continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and completed a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Prior to joining the Levine Cancer Institute, he was an Associate Professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill where he led their Multiple Myeloma Program.

Jonathan Kaufman, MD, is Associate Professor and Associate Vice-Chair for Quality and Safety of the Department of Hematology and Medical Oncology at the Emory University School of Medicine. Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant. His research focus is on the development of optimal treatment regimens and new drug development for patients with plasma cell disorders. Additionally, Dr. Kaufman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with American Society of Clinical Oncology and American Society of Hematology. Dr. Kaufman earned his Medical Degree from the Medical College of Georgia in Augusta. He subsequently completed his Residency in Internal Medicine and his Fellowship in Hematology and Oncology at Emory University.

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

Michaela Liedtke, MD, is Associate Professor of Medicine (Hematology) at the Stanford University Medical Center in Palo Alto, CA and Co-Director of the Stanford Amyloid Center. She treats multiple myeloma, amyloidosis, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and other hematological malignancies. Dr. Liedtke has been an investigator in a number of myeloma-related clinical trials including CAR T therapies, novel therapies for relapsed/refractory disease, disease status with cardiac issues, and plasma cell leukemia. She is a member of the National Comprehensive Cancer Network (NCCN) panel that publishes and updates myeloma treatment guidelines. Dr. Liedtke served in fellowships at Stanford and Memorial Sloan-Kettering Cancer Center in New York, NY. She completed her medical residency at the Albert Einstein College of Medicine in New York, NY and earned her medical degree at the Medizinische Hochschule Hannover, Germany.